BlackRock
FTH

BlackRock’s Faeth Therapeutics FTH Stock Holding History

BlackRock’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85K Buy
+3,402
New +$78.7K ﹤0.01% 5042
2024
Q3 		– Sell
-389
Closed -$4.82K – 5310
2024
Q2 		$4.82K Sell
389
-1,290
-77% -$26.8K ﹤0.01% 5128
2024
Q1 		$35.3K Sell
1,679
-62
-4% -$1.07K ﹤0.01% 4942
2023
Q4 		$24.1K Sell
1,741
-20
-1% -$273 ﹤0.01% 5063
2023
Q3 		$28.2K Sell
1,761
-72
-4% -$1.55K ﹤0.01% 5095
2023
Q2 		$41.8K Sell
1,833
-72
-4% -$2.11K ﹤0.01% 5095
2023
Q1 		$57.2K Buy
1,905
+61
+3% +$1.81K ﹤0.01% 5094
2022
Q4 		$54.9K Sell
1,844
-6,854
-79% -$202K ﹤0.01% 5202
2022
Q3 		$270K Sell
8,698
-247
-3% -$9.71K ﹤0.01% 4895
2022
Q2 		$406K Sell
8,945
-49,456
-85% -$1.85M ﹤0.01% 4840
2022
Q1 		$2.7M Sell
58,401
-1,735
-3% -$138K ﹤0.01% 4269
2021
Q4 		$6.97M Buy
60,136
+10,120
+20% +$1.51M ﹤0.01% 3854
2021
Q3 		$10.5M Buy
50,016
+31,843
+175% +$5.8M ﹤0.01% 3649
2021
Q2 		$3.55M Buy
18,173
+1,538
+9% +$380K ﹤0.01% 4024
2021
Q1 		$4.83M Buy
+16,635
New +$5.57M ﹤0.01% 3956

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

BlackRock's FTH Position: Q2 2026 in Review

BlackRock opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 3,402 shares worth $85K. The stake represents ﹤0.01% of the portfolio and ranks #5042 among its holdings. This is a return to the name: BlackRock previously reported a position in FTH as recently as Q2 2024.

BlackRock first reported a position in FTH in Q1 2021 and has held it in 15 quarters since. The position peaked at $10.5M in Q3 2021. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • BlackRock held 3,402 shares of Faeth Therapeutics worth $85K as of Q2 2026.
  • Faeth Therapeutics was a new BlackRock position in Q2 2026.
  • Faeth Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5042 holding.
  • BlackRock first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • BlackRock's Faeth Therapeutics position peaked at $10.5M in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.